Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.41 |
| ▸ | WNT3A | P56704 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenethylamine SCHEMBL4960273 | 0.89 | NR4A2 (0.40) | NR4A2ALDH1A1CYP2C19CYP1A2HPGD | |
| SCHEMBL24171989 | 0.85 | ACHE (0.44) | ACHEKCNN4CTNNB1WNT3AKMT2A | |
| SCHEMBL31121938 | 0.85 | ACHE (0.44) | ACHEKCNN4CTNNB1WNT3AKMT2A | |
| SCHEMBL31121940 | 0.84 | ACHE (0.43) | ACHEKCNN4CTNNB1WNT3AKMT2A | |
| SCHEMBL14621794 | 0.84 | ACHE (0.43) | ACHEKCNN4CTNNB1WNT3AKMT2A | |
| SCHEMBL24171802 | 0.84 | ACHE (0.43) | ALDH1A1ACHEKCNN4CTNNB1WNT3A | |
| SCHEMBL24171986 | 0.84 | ACHE (0.43) | ACHEKCNN4CTNNB1WNT3AKMT2A | |
| SCHEMBL4960271 | 0.82 | KMT2A (0.53) | NR4A2ALDH1A1CYP2C19CYP1A2HPGD | |
| SCHEMBL15547072 | 0.80 | ELANE (0.52) | ALDH1A1CYP2C19CYP1A2HPGDKCNN4 | |
| SCHEMBL4960277 | 0.79 | MEN1 (0.39) | ALDH1A1HPGDACHEKMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401816-B1 | PROCESS FOR THE PRODUCTION OF THE PIPERIDINE DERIVATIVE FEXOFENADINE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-02-13 | — | — | EP | disclosed |
| US-7235665-B2 | Process for the production of piperidine derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-06-26 | — | — | US | disclosed |
| CN-1229347-C | Process for preparing piperidine derivative fexofenadine | AVENTIS PHARMA GMBH (DE) | 2005-11-30 | — | — | CN | disclosed |
| US-20040198983-A1 | Process for the production of piperidine derivatives | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-10-07 | — | — | US | disclosed |
| CN-1516689-A | Process for production of piperidine derivative fexofenadine | ������ҽҩ�¹�����˾ | 2004-07-28 | — | — | CN | disclosed |
| US-6743941-B2 | INCLUDING FEXOFENADINE, USING THE CLAIMED CHEMICAL INTERMEDIATE, P-(2-CARBOXYETHYLCARBONYL)-ALPHA,ALPHA-DIMETHYLPHENYLACETIC ACID, ALKYL ESTER | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-01 | — | — | US | disclosed |
| EP-1401816-A1 | PROCESS FOR THE PRODUCTION OF THE PIPERIDINE DERIVATIVE FEXOFENADINE | Aventis Pharma Deutschland GmbH (DE) | 2004-03-31 | — | — | EP | disclosed |
| US-20030105329-A1 | Process for the production of piperidine derivatives | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| WO-2002102776-A1 | PROCESS FOR THE PRODUCTION OF THE PIPERIDINE DERIVATIVE FEXOFENADINE | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105329-A1 | Process for the production of piperidine derivatives | HRH2, HRH1, HRH4 | NR4A2 1967/4885ALDH1A1 289/4885CYP2C19 16/4885 |
| US-20040198983-A1 | Process for the production of piperidine derivatives | HRH2, HRH1, HRH4 | NR4A2 1967/4885ALDH1A1 289/4885CYP2C19 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.